Payment overview · 2025
General Payments
$63.50
1 reported records · 1 companies
Healthcare provider profile · identity verified
Syed A Ali, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOONVILLE, IN · NPI 1528055662
Verified facts
What the public records show
CMS Open Payments records show Syed A Ali, MD received $63.50 in general payments during 2025 across 1 reported records.
Janssen Biotech, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $63.50 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $63.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 973 | 97 |
| Gabapentin | Gabapentin | 566 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 535 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 506 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 41 |
| Furosemide | Furosemide | 420 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 43 |
| Tramadol Hcl | Tramadol Hcl | 320 | 38 |
| Eliquis | Apixaban | 319 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 314 | 27 |
| Lisinopril | Lisinopril | 303 | 49 |
| Donepezil Hcl | Donepezil Hcl | 290 | 30 |
| Meloxicam | Meloxicam | 284 | 30 |
| Sertraline Hcl | Sertraline Hcl | 269 | 25 |
| Potassium Chloride | Potassium Chloride | 257 | 39 |
| Metformin Hcl | Metformin Hcl | 242 | 28 |
| Omeprazole | Omeprazole | 230 | 28 |
| Alprazolam | Alprazolam | 228 | 36 |
| Losartan Potassium | Losartan Potassium | 224 | 22 |
| Buspirone Hcl | Buspirone Hcl | 222 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 167 | 32 |
| Mirtazapine | Mirtazapine | 163 | 18 |
| Trazodone Hcl | Trazodone Hcl | 161 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 24 |
| Spironolactone | Spironolactone | 148 | 16 |
| Famotidine | Famotidine | 142 | suppressed |
| Celecoxib | Celecoxib | 135 | suppressed |
| Carvedilol | Carvedilol | 132 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 20 |
| Olanzapine | Olanzapine | 128 | 12 |
| Clonazepam | Clonazepam | 126 | 12 |
| Ibuprofen | Ibuprofen | 126 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 122 | 14 |
| Allopurinol | Allopurinol | 120 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 120 | suppressed |
| Levetiracetam | Levetiracetam | 105 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | suppressed |
| Memantine Hcl | Memantine Hcl | 97 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 96 | suppressed |
| Baclofen | Baclofen | 87 | suppressed |
| Risperidone | Risperidone | 82 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 17 |
| Simvastatin | Simvastatin | 76 | suppressed |
| Lorazepam | Lorazepam | 74 | 11 |
| Meclizine Hcl | Meclizine Hcl | 74 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 11 |
| Ezetimibe | Ezetimibe | 71 | 11 |
| Loperamide | Loperamide Hcl | 70 | 20 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 16 |
| Azithromycin | Azithromycin | 64 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 14 |
| Pregabalin | Pregabalin | 63 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 63 | suppressed |
| Temazepam | Temazepam | 63 | suppressed |
| Finasteride | Finasteride | 60 | suppressed |
| Cephalexin | Cephalexin | 58 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Glipizide Er | Glipizide | 57 | 14 |
| Glipizide | Glipizide | 56 | 13 |
| Verapamil Er | Verapamil Hcl | 54 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 16 |
| Admelog Solostar | Insulin Lispro | 49 | suppressed |
| Carbamazepine Er | Carbamazepine | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 13 |
| Topiramate | Topiramate | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 14 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Prednisone | Prednisone | 30 | 17 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Ondansetron Odt | Ondansetron | 18 | 15 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Levocarnitine | Levocarnitine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.50 · 1 records | Janssen Biotech, Inc. | TREMFYA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error